Comprehensive cooperation of cell culture technology between GEKO biology and sartorius

[China Pharmaceutical network enterprise news] Shanghai | Tianjin, September 21, 2017 - Geke (Tianjin) biomedical Co., Ltd and sartorius Stedim biotechnology, a subsidiary of Sartorius Group, announced that the two sides formally signed an agreement on upstream technology development of cell culture and established a close strategic partnership Today, the two sides held a signing ceremony at Hilton Shimao Hotel, Tianjin eco city, China In this technical cooperation, both sides will carry out comprehensive technical development for cell culture technology in the field of gene therapy The breakthrough of large-scale cell serum-free suspension culture technology is the key to the treatment of new targeted gene drugs and recombinant vaccine production technology The cooperation will use the automated high-throughput cell culture platform and online monitoring technology to carry out comprehensive process research, so as to achieve major technological breakthroughs in this field, so as to accelerate the research and development and production capacity of domestic tumor targeted drugs "As a partner of pharmaceutical enterprises and an industry leader in upstream technology, sartorius strongly supports the rapid development of China's biopharmaceutical industry from four aspects: accelerating clinical access, improving protein expression, and quality from design and stable production." Dr Joerg lindenblatt, vice president, Asia Pacific region of sedolis, said, "Gekko biology and sedolis hold the same idea in innovation and quality The technical cooperation between the two sides will open a new chapter for targeted treatment of brain tumors, and the drug quality will also be comparable to the international standards in Europe and the United States At the same time, sartorius will also provide comprehensive support for the platform construction of North America R & D Department of GEKO biology and technology transfer between China and the United States, so as to quickly land new technology in China It is believed that this cooperation will lay the foundation for the long-term sustainable development of both sides and promote the development of China's health cause with innovative drugs " "As a new force in the development of innovative biopharmaceuticals, gemco biology is committed to the research and development of high-quality anti-tumor and anti infection biopharmaceuticals It is expected that in the future, it will develop and produce multiple biopharmaceuticals, including targeted treatment of brain cancer, to make good social benefits for the health industry." Dr Zhu Jianwei, CEO and scientist of GEKO biology, said, "the technical cooperation with sartorius will help to introduce innovative research concepts and global technology platforms, accelerate the development of targeted immunotherapy drugs, and pave the way for the production of innovative drugs." In this technical cooperation, sartorius will provide a cell culture platform covering R & D, pilot test and commercial production for GEKO biology, and provide strong technical support with rich experience of global pharmaceutical enterprises This technical cooperation will surely help China's medical industry take off with its technological innovation About Jieke biology, an enterprise invested and established in China by jecho laboratories, Inc., an American biopharmaceutical company, is located in Zhongxin Tianjin Ecological City, Binhai New Area, Tianjin, and is building a biomedical R & D and production base that has reached the world's advanced level The base will be constructed in two phases, focusing on the research and development of innovative biological drugs for the treatment of major human diseases (such as cancer and infectious diseases) At present, the first phase of the project is close to the end After the whole project is completed and put into operation, the estimated output value is more than 5 billion yuan, and about 1500 jobs can be provided for the local area At the same time, it enriches the biomedical industry chain in North China, and will create huge economic benefits and good social benefits in the future Sartorius Stedim biotech is an international supplier of equipment and services for the biopharmaceutical industry, providing safe, timely and economic integrated solutions for the development and production of global biopharmaceuticals As a supplier of complete solutions, sedolistei offers a portfolio of products covering almost all steps of the biopharmaceutical process The company is committed to promoting disposable technology and value-added services to meet the rapid development of the biopharmaceutical industry The company is headquartered in oubanie, France and listed on the European exchange in Paris It is famous for its production and R & D centers in Europe, North America and Asia, as well as its worldwide sales network.